Dinapsoline

Chemical compound
  • none
Identifiers
  • 8,9-dihydroxy-2,3,7,11b-tetrahydro-1H-naph[1,2,3-de]isoquinoline
CAS Number
  • 458563-40-1 checkY
PubChem CID
  • 9816455
ChemSpider
  • 7992205 ☒N
UNII
  • GZ9XC6C5P9
CompTox Dashboard (EPA)
  • DTXSID50431229 Edit this at Wikidata
Chemical and physical dataFormulaC16H15NO2Molar mass253.301 g·mol−13D model (JSmol)
  • Interactive image
  • Oc1c3c(ccc1O)[C@H]4c2c(cccc2C3)CNC4
InChI
  • InChI=1S/C16H15NO2/c18-14-5-4-11-12(16(14)19)6-9-2-1-3-10-7-17-8-13(11)15(9)10/h1-5,13,17-19H,6-8H2/t13-/m0/s1 ☒N
  • Key:ZQTSNGJHMUKLOM-ZDUSSCGKSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Dinapsoline is a drug developed for the treatment of Parkinson's disease,[1] that acts as a selective full agonist at the dopamine D1 receptor.[2][3][4][5]

References

  1. ^ Gulwadi AG, Korpinen CD, Mailman RB, Nichols DE, Sit SY, Taber MT (February 2001). "Dinapsoline: characterization of a D1 dopamine receptor agonist in a rat model of Parkinson's disease". The Journal of Pharmacology and Experimental Therapeutics. 296 (2): 338–44. PMID 11160615.
  2. ^ Ghosh D, Snyder SE, Watts VJ, Mailman RB, Nichols DE (January 1996). "9-Dihydroxy-2,3,7,11b-tetrahydro-1H-naph[1,2,3-de]isoquinoline: a potent full dopamine D1 agonist containing a rigid-beta-phenyldopamine pharmacophore". Journal of Medicinal Chemistry. 39 (2): 549–55. doi:10.1021/jm950707+. PMID 8558526.
  3. ^ Sit SY, Xie K, Jacutin-Porte S, Taber MT, Gulwadi AG, Korpinen CD, Burris KD, Molski TF, Ryan E, Xu C, Wong H, Zhu J, Krishnananthan S, Gao Q, Verdoorn T, Johnson G (August 2002). "(+)-Dinapsoline: an efficient synthesis and pharmacological profile of a novel dopamine agonist". Journal of Medicinal Chemistry. 45 (17): 3660–8. doi:10.1021/jm0101545. PMID 12166939.
  4. ^ Sit SY, Xie K, Jacutin-Porte S, Boy KM, Seanz J, Taber MT, Gulwadi AG, Korpinen CD, Burris KD, Molski TF, Ryan E, Xu C, Verdoorn T, Johnson G, Nichols DE, Mailman RB (February 2004). "Synthesis and SAR exploration of dinapsoline analogues". Bioorg. Med. Chem. 12 (4): 715–34. doi:10.1016/j.bmc.2003.11.015. PMID 14759732.
  5. ^ Gleason SD, Witkin JM (May 2006). "Effects of dopamine D1 receptor agonists in rats trained to discriminate dihydrexidine". Psychopharmacology. 186 (1): 25–31. doi:10.1007/s00213-006-0342-2. PMID 16575553. S2CID 2159983.
  • v
  • t
  • e
Stimulants
Adamantanes
Adenosine antagonistsAlkylaminesAmpakinesArylcyclohexylaminesBenzazepinesCathinonesCholinergicsConvulsantsEugeroicsOxazolinesPhenethylamines
PhenylmorpholinesPiperazinesPiperidinesPyrrolidinesRacetamsTropanesTryptaminesOthers
  • v
  • t
  • e
D1-like
Agonists
PAMs
Antagonists
D2-like
Agonists
Antagonists
  • See also: Receptor/signaling modulators
  • Adrenergics
  • Serotonergics
  • Monoamine reuptake inhibitors
  • Monoamine releasing agents
  • Monoamine metabolism modulators
  • Monoamine neurotoxins


Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

  • v
  • t
  • e